細胞療法製造の市場規模、シェア、成長分析、療法タイプ別、細胞源別、事業規模別、地域別 - 産業予測、2025年～2032年

細胞療法製造の世界市場規模は2023年に47億2,000万米ドルとなり、2024年の56億4,000万米ドルから2032年には248億5,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは20.4%で推移する見通しです。

細胞療法製造の状況は、需要の増加と高度な生産技術の必要性によって急速に進化しています。新しい施設は、自動化、クローズドシステムバイオリアクター、高度な分析を統合し、一貫した製品供給と規制基準の遵守を確実にしています。しかし、この分野は、開発・製造受託企業を標的とした頻繁なサイバー攻撃によって浮き彫りになったデータプライバシーリスクなど、重大な課題に直面しています。この業界の企業の驚くべき割合がサイバー事件を報告しており、強固なエンドツーエンドのデータ保護の必要性が浮き彫りになっています。さらに、製造の複雑性が高まった結果、規制当局の監視の目が厳しくなり、品質管理の問題によるリコールやコンプライアンス上の警告が当局から頻繁に出されるようになりました。これらの力学は、拡大する市場におけるイノベーションと患者の安全という2つの課題を物語っています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 技術分析
• ケーススタディ
• 顧客購買行動分析

細胞療法製造市場規模：療法タイプ別& CAGR（2025-2032）

• 市場概要
• T細胞療法
• 幹細胞療法
• 樹状細胞療法

細胞療法製造市場規模：細胞源別& CAGR（2025-2032）

• 市場概要
• 自家移植
• 同種異系
• 特定不能

細胞療法製造市場規模：事業規模別& CAGR（2025-2032）

• 市場概要
• 臨床用
• 商業用

細胞療法製造市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024年）

主要企業プロファイル

• AGC Biologics
• Charles River Laboratories
• FUJIFILM Cellular Dynamics
• Thermo Fisher Scientific
• WuXi AppTec
• Lonza
• Catalent
• BioNTech
• Cell and Gene Therapy Catapult
• Cell Therapies Pty Ltd
• Merck KGaA
• Takara Bio
• Bristol Myers Squibb
• Novartis

結論と提言

Global Cell Therapy Manufacturing Market size was valued at USD 4.72 Billion in 2023 and is poised to grow from USD 5.64 Billion in 2024 to USD 24.85 Billion by 2032, growing at a CAGR of 20.4 % in the forecast period (2025-2032).

The cell therapy manufacturing landscape is evolving rapidly, driven by increasing demand and the need for advanced production techniques. New facilities are integrating automation, closed system bioreactors, and sophisticated analytics to ensure consistent product supply and compliance with regulatory standards. However, this sector faces significant challenges, including data privacy risks highlighted by frequent cyberattacks targeting contract development and manufacturing organizations. An alarming percentage of firms in the industry have reported cyber incidents, underscoring a critical need for robust end-to-end data protection. Moreover, heightened manufacturing complexity has resulted in more regulatory scrutiny, with frequent recalls and compliance warnings from authorities due to quality control issues. These dynamics illustrate the dual challenge of innovation and patient safety in the expanding market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cell Therapy Manufacturing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cell Therapy Manufacturing Market Segments Analysis

The global cell therapy manufacturing marketis segmented into therapy type, cell source, scale of operation, and region. By therapy type, the market is classified into T cell therapies, stem cell therapies, and dendritic cell therapies. Depending on the cell source, it is divided into autologous, allogeneic, and unspecified. According to scale of operation , the market is categorized into clinical and commercial. Regionally, it is analyzed across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

Driver of the Global Cell Therapy Manufacturing Market

The increasing prevalence of chronic diseases such as cancer and autoimmune disorders significantly propels the global cell therapy manufacturing market. The rising number of cancer cases generates a heightened demand for advanced therapies, including CAR-T and stem cell treatments. This demand stimulates substantial investments in production technologies and innovations in scalable manufacturing solutions, empowering biotech companies to address unmet medical needs effectively. As a result, there is a concerted effort to improve market access, particularly in the fields of oncology and regenerative medicine, ensuring that cutting-edge therapies are developed and made available to a larger population of patients.

Restraints in the Global Cell Therapy Manufacturing Market

The Global Cell Therapy Manufacturing market faces significant constraints due to the intricate nature and high costs associated with the production processes. Customized treatments, such as CAR-T therapies, require specialized facilities and expert personnel, often resulting in expenses exceeding $500,000 per patient. These financial barriers restrict access, particularly in lower-income regions, and create challenges for scaling operations. Additionally, the variability in cell quality and the lengthy production timelines further complicate manufacturing processes, making it increasingly difficult for companies to establish and expand their market presence effectively. This combination of factors contributes to a restrained growth outlook for the industry.

Market Trends of the Global Cell Therapy Manufacturing Market

The Global Cell Therapy Manufacturing market is witnessing a significant trend towards the adoption of automation and closed system technologies, enhancing both efficiency and scalability in production processes. These advancements, including the utilization of robotic systems and bioreactors, are instrumental in minimizing human handling, thereby reducing contamination risks. Closed systems, particularly single-use bioreactors, ensure sterility and compliance with Good Manufacturing Practices (GMP). This technological shift not only lowers operational costs but also accelerates production timelines, especially for allogeneic therapies, allowing manufacturers to effectively meet rising demand in oncological and regenerative medicine sectors across North America and the Asia-Pacific.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Cell Therapy Manufacturing Market Size by Therapy Type & CAGR (2025-2032)

• Market Overview
• T cell therapies
• Stem cell therapies
• Dendritic cell therapies

Global Cell Therapy Manufacturing Market Size by Cell Source & CAGR (2025-2032)

• Market Overview
• Autologous
• Allogeneic
• Unspecified

Global Cell Therapy Manufacturing Market Size by Scale of Operation & CAGR (2025-2032)

• Market Overview
• Clinical
• Commercial

Global Cell Therapy Manufacturing Market Size & CAGR (2025-2032)

• North America (Therapy Type, Cell Source, Scale of Operation)
  • US
  • Canada
• Europe (Therapy Type, Cell Source, Scale of Operation)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Cell Source, Scale of Operation)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Cell Source, Scale of Operation)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Cell Source, Scale of Operation)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AGC Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• FUJIFILM Cellular Dynamics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi AppTec
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cell and Gene Therapy Catapult
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cell Therapies Pty Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takara Bio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations